A small biotech nearing a clinical milestone
TheraCryf plc (LSE:TCF), the neuropsychiatry drug developer, published final results for the year ended 31 March 2026 on 28 September 2026, setting out plans to move its lead orexin-1 programme towards a first-in-human trial in Australia. The results came weeks after a £1.05m fundraising and were followed on 2 October 2026 by an announcement that an Australian partner would help progress the Phase 1 trial. The auditor flagged a material uncertainty over going concern, underlining that the company will need further funding.
What the company does
Headquartered at Alderley Park in Cheshire, TheraCryf develops medicines for addiction and other neuropsychiatric disorders using a capital-light, virtual model. It aims to advance programmes to early clinical or proof-of-concept stage before seeking partners. Its lead asset is an orexin-1 receptor antagonist, known as Ox-1, for addiction. It also has a dopamine transporter programme targeting fatigue in conditions such as multiple sclerosis, and a legacy grant-funded glioblastoma programme, SFX-01.
Latest developments
According to the results, the Ox-1 programme is in late-stage preclinical development, with clinic-enabling work expected to be completed in the fourth quarter of 2026. Drug substance production reached 10.6kg, a further GMP batch of 2.57kg followed after the period end, and first-species GLP toxicology showed a wide safety margin. A second-species study is under way, with final data due in the fourth quarter. A process patent filing could extend protection to 2046. The company incorporated TheraCryf Australia Pty Ltd in May 2026 to support the trial.
Earlier, on 14 April 2026, the board rejected an unsolicited, non-binding proposal to acquire its Ox-1 and dopamine transporter assets, saying it did not reflect their value or commercial potential. The proposer was not named. On 9 October 2026 the company announced a change of nominated adviser.
Financial picture
The post-tax loss widened to £3.5m from £1.9m as external R&D spending rose to £1.5m. Cash and short-term deposits stood at £1.5m at 31 March 2026, down from £4.1m. In September 2026 the company raised £1.05m gross through a placing and subscription at 0.18p per share, issuing about 583 million new shares. It estimates its cash runway extends to the end of the first quarter of 2027. No dividend is paid.
Sector and index context
TheraCryf is one of the smallest healthcare names in the FTSE AIM All Share Index. Early-stage biotech companies on AIM have often struggled to raise capital on attractive terms, and many rely on partnering deals to fund clinical work. The company points to large commercial deals in the orexin field as evidence of interest in the mechanism, though such comparisons do not guarantee value for its own assets.
Key risks
Funding is the most pressing risk, given the going concern uncertainty and short runway. Further raises at low share prices would dilute shareholders heavily. Preclinical data may not translate into clinical success, regulatory approvals for the Phase 1 trial are still required and partnering talks may not succeed.
What to watch next
Investors will watch for completion of GLP toxicology and manufacturing reports in the fourth quarter, regulatory and ethics submissions in Australia, the start of the Phase 1 study, any partnering agreement and plans to secure funding beyond early 2027. The role of the Australian partner announced on 2 October, and how much of the trial cost it may absorb, will be important in judging how far existing cash can stretch. Any progress on the dopamine transporter programme would also broaden the company's story.






Please wait processing your request...